MA43794A - Procédés de prédiction de l'utilité de néoantigènes pour l'immunothérapie - Google Patents

Procédés de prédiction de l'utilité de néoantigènes pour l'immunothérapie

Info

Publication number
MA43794A
MA43794A MA043794A MA43794A MA43794A MA 43794 A MA43794 A MA 43794A MA 043794 A MA043794 A MA 043794A MA 43794 A MA43794 A MA 43794A MA 43794 A MA43794 A MA 43794A
Authority
MA
Morocco
Prior art keywords
methods
immunotherapy
predicting
neoantigens
tumor
Prior art date
Application number
MA043794A
Other languages
English (en)
Other versions
MA43794B1 (fr
Inventor
Sebastian Boegel
Martin Löwer
Ugur Sahin
Barbara Schrörs
Mathias Vormehr
Original Assignee
Biontech Rna Pharmaceuticals Gmbh
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Rna Pharmaceuticals Gmbh, Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical Biontech Rna Pharmaceuticals Gmbh
Publication of MA43794A publication Critical patent/MA43794A/fr
Publication of MA43794B1 publication Critical patent/MA43794B1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne des procédés de prédiction de l'utilité de peptides ou de polypeptides tels que des épitopes de lymphocytes t pour l'immunothérapie, par exemple pour la vaccination. En particulier, la présente invention concerne des procédés pour prédire si des peptides ou des polypeptides tels que des antigènes ou des épitopes associés à une tumeur, en particulier des néoantigènes ou néoépitopes associés à une tumeur, sont immunogènes et, en particulier, utiles pour l'immunothérapie, par exemple pour la vaccination. Les procédés selon l'invention peuvent être utilisés en particulier pour fournir des vaccins qui sont spécifiques d'une tumeur d'un patient et, donc, dans le contexte de vaccins anticancéreux personnalisés.
MA43794A 2016-05-13 2017-05-10 Procédés de prédiction de l'utilité de néoantigènes pour l'immunothérapie MA43794B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2016/060897 WO2017194170A1 (fr) 2016-05-13 2016-05-13 Procédés pour prédire l'utilité de protéines ou de fragments de protéines pour l'immunothérapie
PCT/EP2017/061196 WO2017194610A1 (fr) 2016-05-13 2017-05-10 Procédés de prédiction de l'utilité de protéines ou de fragments de protéines pour l'immunothérapie

Publications (2)

Publication Number Publication Date
MA43794A true MA43794A (fr) 2019-03-20
MA43794B1 MA43794B1 (fr) 2020-12-31

Family

ID=55971007

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43794A MA43794B1 (fr) 2016-05-13 2017-05-10 Procédés de prédiction de l'utilité de néoantigènes pour l'immunothérapie

Country Status (26)

Country Link
US (1) US20190178871A1 (fr)
EP (2) EP3455625B1 (fr)
JP (2) JP2019520554A (fr)
KR (2) KR102358620B1 (fr)
CN (1) CN109073637A (fr)
AU (2) AU2017264546B2 (fr)
BR (1) BR112018073221A2 (fr)
CA (1) CA3022654A1 (fr)
CY (1) CY1123520T1 (fr)
DK (2) DK3792628T3 (fr)
ES (1) ES2826480T3 (fr)
FI (1) FI3792628T3 (fr)
HR (1) HRP20201671T1 (fr)
HU (1) HUE052240T2 (fr)
IL (2) IL300841A (fr)
LT (2) LT3455625T (fr)
MA (1) MA43794B1 (fr)
MD (1) MD3455625T2 (fr)
MX (2) MX2018013081A (fr)
PL (1) PL3455625T3 (fr)
PT (1) PT3455625T (fr)
RS (1) RS61071B1 (fr)
SG (1) SG11201808495SA (fr)
SI (1) SI3455625T1 (fr)
WO (2) WO2017194170A1 (fr)
ZA (1) ZA201805809B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3754022A4 (fr) * 2018-02-15 2021-09-29 National University Corporation Asahikawa Medical University Peptide antigénique de cancer
CN109021062B (zh) * 2018-08-06 2021-08-20 倍而达药业（苏州）有限公司 一种肿瘤新抗原的筛选方法
CN111621564B (zh) * 2019-02-28 2022-03-25 武汉大学 一种鉴定有效肿瘤新抗原的方法
CN110534156B (zh) * 2019-09-02 2022-06-17 深圳市新合生物医疗科技有限公司 一种提取免疫治疗新抗原的方法及系统
CN111487399B (zh) * 2020-03-26 2021-09-17 湖南师范大学 一种蛋白分子标记在鱼类生殖细胞发育研究中的应用
CA3227081A1 (fr) 2021-08-24 2023-03-02 Irena RABE Technologies de transcription in vitro
WO2024083345A1 (fr) 2022-10-21 2024-04-25 BioNTech SE Procédés et utilisations associés à des compositions liquides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766205B1 (fr) * 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US20090214494A1 (en) * 2005-03-29 2009-08-27 The Board Of Trustees Of The University Of Illinoi Cancer Vaccines and Therapeutic Methods
JP2009273377A (ja) * 2008-05-12 2009-11-26 Igaku Seibutsugaku Kenkyusho:Kk Ｍｈｃクラスｉ分子と結合し癌細胞の表面に表出されるペプチド候補の選択方法
TW201000119A (en) * 2008-06-10 2010-01-01 Oncotherapy Science Inc MYBL2 epitope peptides and vaccines containing the same
RS53782B1 (en) * 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh TUMOR-ASSOCIATED PEPTIDES PREPARED AND ANTI-CHANGE RESPONSE FOR GLIOBLASTOMA (GBM) AND OTHER CANCER TREATMENTS
AU2010310468A1 (en) * 2009-10-23 2012-05-24 Mannkind Corporation Cancer immunotherapy and method of treatment
US9266922B2 (en) * 2011-06-01 2016-02-23 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antigen peptide and uses thereof

Also Published As

Publication number Publication date
SI3455625T1 (sl) 2021-01-29
MA43794B1 (fr) 2020-12-31
RU2018137721A (ru) 2020-06-15
PL3455625T3 (pl) 2021-01-25
BR112018073221A2 (pt) 2019-02-19
EP3455625A1 (fr) 2019-03-20
US20190178871A1 (en) 2019-06-13
WO2017194170A1 (fr) 2017-11-16
CN109073637A (zh) 2018-12-21
LT3792628T (lt) 2024-06-25
DK3455625T3 (da) 2020-10-26
IL262680A (en) 2018-12-31
EP3792628B1 (fr) 2024-04-24
ES2826480T3 (es) 2021-05-18
JP2022081492A (ja) 2022-05-31
KR20190008218A (ko) 2019-01-23
FI3792628T3 (fi) 2024-06-07
EP3792628A3 (fr) 2021-05-19
MX2022007902A (es) 2022-07-21
EP3455625B1 (fr) 2020-09-02
KR102358620B1 (ko) 2022-02-07
CA3022654A1 (fr) 2017-11-16
JP2019520554A (ja) 2019-07-18
LT3455625T (lt) 2021-01-11
EP3792628A2 (fr) 2021-03-17
CY1123520T1 (el) 2022-03-24
MX2018013081A (es) 2019-01-24
AU2017264546B2 (en) 2022-04-28
RS61071B1 (sr) 2020-12-31
AU2017264546A1 (en) 2018-10-18
WO2017194610A1 (fr) 2017-11-16
RU2018137721A3 (fr) 2020-08-25
SG11201808495SA (en) 2018-10-30
MD3455625T2 (ro) 2020-12-31
IL300841A (en) 2023-04-01
HUE052240T2 (hu) 2021-04-28
IL262680B1 (en) 2023-04-01
AU2022209286A1 (en) 2022-08-25
HRP20201671T1 (hr) 2021-03-05
IL262680B2 (en) 2023-08-01
DK3792628T3 (da) 2024-06-17
PT3455625T (pt) 2020-10-22
KR20220020993A (ko) 2022-02-21
ZA201805809B (en) 2020-12-23

Similar Documents

Publication Publication Date Title
MA43794A (fr) Procédés de prédiction de l'utilité de néoantigènes pour l'immunothérapie
MA43435B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre diverses tumeurs (seq id 25 - mrax5-003)
MX2022000012A (es) Prediccion de epitopos de celulas t utiles para vacunacion.
MA41393A1 (fr) Nouveaux peptides et combinaisons de peptides et échafaudages formés de ceux-ci destinés à être utilisés en immunothérapie contre le carcinome colorectal (crc) et d'autres cancers
MA43458A1 (fr) Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitementimmunothérapeutique de divers cancers
CR20200465A (es) Agentes anticuerpos anti-cd25
PH12018502601A1 (en) Anti-b7-h3 antibodies and antibody drug conjugates
GT201700162A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
PH12018502250A1 (en) Cancer immunotherapy by immune activation for immune modulation via globo series antigens
NZ750005A (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
BRPI0416141B8 (pt) anticorpo anti-cd52 modificado, composição farmacêutica, vetores de expressão, e método para preparar uma imunoglobulina
MA31093B1 (fr) Vaccin
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MA40929A (fr) Procédé de production d'anticorps à affinité élevée
CR20200607A (es) INMUNOTERAPIA CONTRA EL MELANOMA Y OTROS TIPOS DE CÁNCER (Divisional 2018-551)
MX2022007833A (es) Nuevos receptores de antigenos quimericos (car) especificos de mesotelina para inmunoterapia de cancer de tumores solidos.
CR20210066A (es) NUEVOS PÉPTIDOS Y ESTRUCTURAS DE SOPORTE PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CARCINOMA EPIDERMOIDE DE CABEZA Y CUELLO Y OTROS DE CÁNCER (Divisional 2019-0094)
PH12020551454A1 (en) Anti-cd25 for tumour specific cell depletion
CR20220061A (es) Anticuerpos que se unen a células cancerosas y que dirigen radionucleidos a dichas células
EA202191979A1 (ru) Композиции и способы ингибирования линиеспецифических антигенов
MA49155B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers
MX2023009434A (es) Anticuerpos contra cd112r y usos de los mismos.
MA42022A1 (fr) Nouveaux peptides, combinaisons de peptides et supports pour utilisation dans le traitement immunothérapeutique de divers cancers
CR20200477A (es) PÉPTIDOS Y COMBINACIÒN DE PÉPTIDOS NOVEDOSOS PARA SU USO EN INMUNOTERAPIA CONTRA DIVERSOS TUMORES (Divisional 2017-0522)